Lucy van de Wiel, PhD, discusses how infertility is defined as the inability to conceive after 12 months of regular unprotected intercourse, diagnosed through medical history, physical exams and tests, with risk factors including age, lifestyle habits and medical conditions.
Drs Steven Levine, Patricia Ares-Romero, Samuel Nordberg, Martin Rosenzweig, and Carrie Jardine share insight on the future treatment landscape for TRD.
Dr Martin Rosenzweig discusses the importance of data collection to improve patient care in TRD as well as alternative payment models.
University of Washington’s Peter Rabinowitz, M.D., M.P.H., sees a world awash in emerging diseases and climate change data but says it needs to be delivered to clinicians in a form that they can use at the point of care, possibly via the electronic medical record.
The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter Rabinowitz, M.D., M.P.H.
Patients self-identified as members of the minority group that the study was designed to enroll, according to Jeremiah Brown, M.D., of Retina Consultants of Texas, one of the lead ELEVATUM investigators. The study will yield a "treasure trove" of data, Brown said.
Enrollment goals for the U.S. part of the phase 4, open-label study of Vabysmo (faricimab) were 45% Black participants, 45% Hispanic participants and 10% Native American, Pacific Islander and Native Hawaiian, said Jeremiah Brown, M.D., a lead ELEVATUM investigator.
Harmony Garges, M.D, senior vice president, chief medical officer and head of global medical at ViiV Healthcare, highlighted results of two real-world evidence studies of Apretude as an HIV prevention medication.
George O. Waring, IV, M.D., discusses the latest technology improving eyesight for patients.
Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years later according to Prime Therapeutics’ real-world evidence, says Ben Urick, Pharm.D., Ph.D., a health outcomes researcher for the pharmacy benefit manager.
Jeffrey Dunn, Pharm.D., MBA, discusses how key unmet needs in assisted reproductive technology (ART) programs drive ongoing research and innovation, fostering hope for a future where fertility treatments are more effective, accessible and tailored to individual patient needs.
Jeffrey Dunn, Pharm.D., MBA, discusses how quality measures, benchmarking and key performance indicators play a crucial role in their daily work by guiding decision-making, improving patient outcomes and ensuring the continuous enhancement of fertility treatment and assisted reproductive technology (ART) program effectiveness.
Even people living with HIV who have undetectable viral loads experience elevated inflammation levels, explained Michelle Cespedes, M.D., M.S, of Mount Sinai Health System.
Only a small group of patients have started the process to receive the new gene therapies for sickle cell disease, says Kevin Niehoff, Pharm.D., of IPD Analytics.
Drs Martin Rosenzweig and Samuel Nordberg share perspectives for integrated policymaking in behavioral health, as well as payer and provider collaboration for TRD.
Carrie Jardine leads a discussion on varying prior authorization policies for alternative therapies for TRD along with implications to patients.
Key opinion leaders discuss navigation through challenges with appropriate coding for TRD treatment.
Carrie Jardine and Martin Rosenzweig, MD, share considerations for benefit design in behavioral health.
Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.
A medical expert in infertility discusses how best practices in communicating benefits for fertility treatments and assisted reproductive technology (ART) programs involve clear, concise and accessible information delivery and tailoring messages to diverse patient populations to ensure comprehensive understanding of coverage options and treatment processes.
Jeffrey Dunn, Pharm.D., MBA, discusses how social determinants of health and population health factors are integrated into decision-making processes for fertility treatments and assisted reproductive technology (ART) programs to ensure equitable access and improve overall outcomes across diverse patient populations.
A key opinion leader discusses how comprehensive fertility/ assisted reproductive technology (ART) programs should include a range of services to provide holistic care for individuals and couples seeking to conceive.
Jeffrey Dunn, Pharm.D., MBA, discusses how the overall issues for assisted reproductive technologies (ARTs) encompass a range of challenges, including access, affordability, efficacy and ethical considerations, and the need for continued research and improvement in treatment protocols
Dr. Podesta discuss the managed care coverage challenges related to PDTs and explore strategies for improving patient access, while also addressing methods for evaluating patient outcomes and satisfaction with PDTs.
The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while emphasizing the importance of collaboration between providers and payers to ensure patient access to various ARTs.
Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.
Samuel Nordberg, PhD, discusses challenges with the definition and identification of TRD in the clinical setting.
Drs Samuel Nordberg, Patricia Ares-Romero, and Martin Rosenzweig share considerations for effective care delivery for patients with TRD.
Dr. Samuel Nordberg discusses methods for identifying patients in need of an alternative therapy for TRD at the health system level.
Dr. Seminerio predicts how the future landscape will change for intravenous and subcutaneous biologics.
